185 related articles for article (PubMed ID: 20823195)
41. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL; Das P; Golde TE
FASEB J; 2006 Dec; 20(14):2576-8. PubMed ID: 17068112
[TBL] [Abstract][Full Text] [Related]
42. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.
Lee EB; Leng LZ; Zhang B; Kwong L; Trojanowski JQ; Abel T; Lee VM
J Biol Chem; 2006 Feb; 281(7):4292-9. PubMed ID: 16361260
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy.
Beckmann N; Gérard C; Abramowski D; Cannet C; Staufenbiel M
J Neurosci; 2011 Jan; 31(3):1023-31. PubMed ID: 21248127
[TBL] [Abstract][Full Text] [Related]
44. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
[TBL] [Abstract][Full Text] [Related]
45. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice.
Paganetti P; Reichwald J; Bleckmann D; Abramowski D; Ammaturo D; Barske C; Danner S; Molinari M; Müller M; Papin S; Rabe S; Schmid P; Staufenbiel M
Neurobiol Aging; 2013 Dec; 34(12):2866-78. PubMed ID: 23870837
[TBL] [Abstract][Full Text] [Related]
46. [Aβ immunotherapy for Alzheimer's disease].
Sakai K; Yamada M
Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
[TBL] [Abstract][Full Text] [Related]
47. [The comparative study on high field MRI and pathology of Alzheimer's disease transgenic mice].
Li MH; Wang PJ; Chen SQ; Zhang W; Gao XL
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(13):876-9. PubMed ID: 21600112
[TBL] [Abstract][Full Text] [Related]
48. Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.
Fitz NF; Castranio EL; Carter AY; Kodali R; Lefterov I; Koldamova R
J Alzheimers Dis; 2014; 41(2):535-49. PubMed ID: 24643138
[TBL] [Abstract][Full Text] [Related]
49. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.
Frost JL; Liu B; Kleinschmidt M; Schilling S; Demuth HU; Lemere CA
Neurodegener Dis; 2012; 10(1-4):265-70. PubMed ID: 22343072
[TBL] [Abstract][Full Text] [Related]
50. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice.
Wilcock DM; Alamed J; Gottschall PE; Grimm J; Rosenthal A; Pons J; Ronan V; Symmonds K; Gordon MN; Morgan D
J Neurosci; 2006 May; 26(20):5340-6. PubMed ID: 16707786
[TBL] [Abstract][Full Text] [Related]
51. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.
Maier M; Seabrook TJ; Lemere CA
Neurodegener Dis; 2005; 2(5):267-72. PubMed ID: 16909008
[TBL] [Abstract][Full Text] [Related]
52. Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice.
Chauhan NB; Siegel GJ; Lichtor T
J Neurosci Res; 2004 Dec; 78(5):732-41. PubMed ID: 15478192
[TBL] [Abstract][Full Text] [Related]
53. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.
Nikolic WV; Bai Y; Obregon D; Hou H; Mori T; Zeng J; Ehrhart J; Shytle RD; Giunta B; Morgan D; Town T; Tan J
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2507-12. PubMed ID: 17264212
[TBL] [Abstract][Full Text] [Related]
54. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-aβ antibodies.
Sehlin D; Hedlund M; Lord A; Englund H; Gellerfors P; Paulie S; Lannfelt L; Pettersson FE
Neurodegener Dis; 2011; 8(3):117-23. PubMed ID: 20714111
[TBL] [Abstract][Full Text] [Related]
55. Cerebral lobar microhemorrhages detection by high magnetic field susceptibility weighted image: a potential diagnostic neuroimage technique of Alzheimer's disease.
Ku HL; Chi NF
Med Hypotheses; 2011 Jun; 76(6):840-2. PubMed ID: 21392891
[TBL] [Abstract][Full Text] [Related]
56. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
57. Progression of Alzheimer's disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy.
Güell-Bosch J; Lope-Piedrafita S; Esquerda-Canals G; Montoliu-Gaya L; Villegas S
NMR Biomed; 2020 May; 33(5):e4263. PubMed ID: 32067292
[TBL] [Abstract][Full Text] [Related]
58. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.
Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K
Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339
[TBL] [Abstract][Full Text] [Related]
59. Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1).
Esteras N; Alquézar C; Bartolomé F; Antequera D; Barrios L; Carro E; Cerdán S; Martín-Requero A
J Alzheimers Dis; 2012; 30(2):337-53. PubMed ID: 22406445
[TBL] [Abstract][Full Text] [Related]
60. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
